- Home
- MHN vs MREO Comparison
MHN vs MREO Comparison
Compare MHN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHN | MREO |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MHN | MREO |
|---|---|---|
| Price | $10.27 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 59.2K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.69 | $1.47 |
| 52 Week High | $10.81 | $3.88 |
Technical Indicators
Market Signals| Indicator | MHN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 50.12 |
| Support Level | $10.25 | $1.89 |
| Resistance Level | $10.34 | $2.37 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.55 | 40.48 |
Price Performance
Historical ComparisonAbout MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).